Salvectors' Cancer Drug Earns Dual US-China Nod with Porton's Help

CRANBURY, N.J. and SUZHOU, China – May 28, 2026 – In a significant step for both cancer therapy and global pharmaceutical development, Salvectors' innovative oncolytic bacteria treatment, YB1-X7 Injection, has received Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA). This achievement, following a prior green light from the U.S. Food and Drug Administration (FDA), marks a critical milestone, enabling the start of global clinical trials and validating a complex cross-border development strategy.

The dual clearance is not only a testament to the promise of Salvectors' novel therapeutic platform but also highlights the pivotal role of its manufacturing partner, Porton Advanced. As the exclusive Contract Development and Manufacturing Organization (CDMO) for the project, Porton Advanced provided the end-to-end support necessary to navigate the rigorous regulatory landscapes of the world's two largest pharmaceutical markets, solidifying a new blueprint for international biotech collaboration.

A New Bacterial Weapon Against Solid Tumors

Salvectors' YB1-X7 represents a cutting-edge approach in the burgeoning field of oncolytic therapy, which uses microorganisms to selectively target and destroy cancer cells. Unlike many conventional treatments that struggle to penetrate deep into tumors, oncolytic bacteria are uniquely suited to thrive in the hypoxic (low-oxygen) cores of solid tumors—areas often resistant to chemotherapy and radiation.

Founded in 2022 by Dr. Bin Yu, Salvectors has built its technology on a proprietary YB1-v3.0 Salmonella bacteria platform. The YB1-X7 Injection is a highly engineered, attenuated strain of Salmonella enterica. It is designed as a nutrient-deficient strain that cannot survive well in healthy, oxygenated tissues, causing it to be rapidly cleared from normal organs. However, within the unique microenvironment of a tumor, it selectively proliferates. This targeted colonization allows YB1-X7 to act as a Trojan horse; it carries plasmids that, once inside the tumor, express and release a potent drug protein, leading to localized tumor cell death and regression.

The therapeutic promise of this approach has now been recognized by top global regulators. Clinical trials for YB1-X7 are designed as open-label, dose-escalation studies to evaluate its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors who have exhausted standard treatment options. The trials will explore both direct intratumoral injection and intravenous infusion, assessing low, medium, and high doses to establish a safe and effective therapeutic window.

The Manufacturing Backbone for Global Ambitions

An innovative drug concept like YB1-X7 can only advance to the clinic with a robust and compliant manufacturing process, a challenge amplified when targeting dual regulatory submissions. This is where the partnership with Porton Advanced proved essential. As a leading CDMO specializing in cell and gene therapies (CGT), Porton Advanced provided the comprehensive Chemistry, Manufacturing, and Controls (CMC) services required to turn a laboratory concept into a clinical-grade product.

From its state-of-the-art facilities in Suzhou, China, Porton Advanced managed the entire production pipeline. This included initial strain construction, process development to optimize bacterial growth and yield, GMP (Good Manufacturing Practice) production of trial supplies, and extensive quality and release testing. According to the company, it employed an innovative purification method specifically designed to remove process-related impurities while maintaining high product recovery and, crucially, the viability of the live bacterial strain.

This success is part of a larger pattern for Porton Advanced, a subsidiary of Porton Pharma Solutions. With dual headquarters in Cranbury, New Jersey, and Suzhou, the company is strategically positioned to bridge the U.S. and Chinese biotech ecosystems. Its 215,000 sq ft GMP-compliant facility in China is equipped for a wide range of advanced therapies. The company has now successfully supported its clients in securing 25 global IND approvals from the NMPA, FDA, and New Zealand's Medsafe, with 12 advanced therapy projects currently in Phase I or II trials. This track record demonstrates a deep expertise in navigating the complex technical and regulatory demands of bringing next-generation medicines to a global stage.

Navigating the Evolving US-China Biotech Corridor

The dual IND clearance for YB1-X7 serves as a powerful case study in the strategic benefits—and inherent complexities—of pursuing parallel drug development in the United States and China. The strategy provides access to vast and diverse patient populations, potentially accelerating clinical trial recruitment and generating data applicable to multiple major markets. In recent years, China's NMPA has made significant reforms to streamline its review processes and align with international standards, reducing the IND review period to as little as 30 days for certain drugs, mirroring the FDA's timeline.

However, this pathway is not without its hurdles. Geopolitical tensions and increasing regulatory scrutiny over data security and supply chain integrity have added layers of complexity to cross-border collaborations. Legislation proposed in the U.S., such as the BIOSECURE Act, has created uncertainty for companies engaging with certain Chinese biotech firms, aiming to protect national security interests. Successfully navigating this landscape requires deep regulatory expertise and a trusted manufacturing partner with a physical and legal presence in both regions.

The Salvectors-Porton Advanced collaboration exemplifies a successful model for mitigating these risks. By leveraging Porton's dual-continent footprint and proven regulatory track record, Salvectors was able to efficiently meet the distinct requirements of both the FDA and NMPA, transforming a potential logistical bottleneck into a strategic advantage.

This success is expected to bolster investor confidence not only in Salvectors but in the oncolytic bacteria field as a whole, which is gaining momentum as a viable new pillar of cancer treatment. For CDMOs, it reinforces the immense value of providing integrated, global-scale manufacturing and regulatory support. As biotech innovation continues to accelerate, such strategic partnerships will be increasingly critical in the global race to bring life-saving therapies from the laboratory to patients worldwide.